Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.

2.50
Hdl Handle:
http://hdl.handle.net/10033/620934
Title:
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.
Authors:
Torge, Afra; Wagner, Stefanie; Chaves, Paula S; Oliveira, Edilene G; Guterres, Silvia S; Pohlmann, Adriana R; Titz, Alexander ( 0000-0001-7408-5084 ) ; Schneider, Marc ( 0000-0002-9260-7357 ) ; Beck, Ruy C R
Abstract:
Treatment of bacterial airway infections is essential for cystic fibrosis therapy. However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are protected from antibiotics and immune response. To overcome this biological barrier, ciprofloxacin was loaded into lipid-core nanocapsules (LNC) for high mucus permeability, sustained release and antibacterial activity. Ciprofloxacin-loaded LNC with a mean size of 180nm showed a by 50% increased drug permeation through mucus. In bacterial growth assays, the drug in the LNC had similar minimum inhibitory concentrations as the free drug in P. aeruginosa and S. aureus. Interestingly, formation of biofilm-like aggregates, which were observed for S. aureus treated with free ciprofloxacin, was avoided by exposure to LNC. With the combined advantages over the non-encapsulated drug, ciprofloxacin-loaded LNC represent a promising drug delivery system with the prospect of an improved antibiotic therapy in cystic fibrosis.
Affiliation:
Helmholtz Institut für pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany.
Citation:
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. 2017, 527 (1-2):92-102 Int J Pharm
Journal:
International journal of pharmaceutics
Issue Date:
10-May-2017
URI:
http://hdl.handle.net/10033/620934
DOI:
10.1016/j.ijpharm.2017.05.013
PubMed ID:
28499793
Type:
Article
Language:
en
ISSN:
1873-3476
Appears in Collections:
publications of the junior research group chemical biology of carbohydrates ([HIPS]CBCH)

Full metadata record

DC FieldValue Language
dc.contributor.authorTorge, Afraen
dc.contributor.authorWagner, Stefanieen
dc.contributor.authorChaves, Paula Sen
dc.contributor.authorOliveira, Edilene Gen
dc.contributor.authorGuterres, Silvia Sen
dc.contributor.authorPohlmann, Adriana Ren
dc.contributor.authorTitz, Alexanderen
dc.contributor.authorSchneider, Marcen
dc.contributor.authorBeck, Ruy C Ren
dc.date.accessioned2017-06-06T14:47:00Z-
dc.date.available2017-06-06T14:47:00Z-
dc.date.issued2017-05-10-
dc.identifier.citationCiprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. 2017, 527 (1-2):92-102 Int J Pharmen
dc.identifier.issn1873-3476-
dc.identifier.pmid28499793-
dc.identifier.doi10.1016/j.ijpharm.2017.05.013-
dc.identifier.urihttp://hdl.handle.net/10033/620934-
dc.description.abstractTreatment of bacterial airway infections is essential for cystic fibrosis therapy. However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are protected from antibiotics and immune response. To overcome this biological barrier, ciprofloxacin was loaded into lipid-core nanocapsules (LNC) for high mucus permeability, sustained release and antibacterial activity. Ciprofloxacin-loaded LNC with a mean size of 180nm showed a by 50% increased drug permeation through mucus. In bacterial growth assays, the drug in the LNC had similar minimum inhibitory concentrations as the free drug in P. aeruginosa and S. aureus. Interestingly, formation of biofilm-like aggregates, which were observed for S. aureus treated with free ciprofloxacin, was avoided by exposure to LNC. With the combined advantages over the non-encapsulated drug, ciprofloxacin-loaded LNC represent a promising drug delivery system with the prospect of an improved antibiotic therapy in cystic fibrosis.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleCiprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Institut für pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany.en
dc.identifier.journalInternational journal of pharmaceuticsen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.